Kamil Malisz, a senior Nextflow Developer at Ardigen, recently presented at the Nextflow Summit 2024. His talk, titled “Advancing Open Science in Big Pharma: Integrating LIMMA/VOOM into the nf-core differential abundance Pipeline,” showcased an impactful collaboration between Ardigen and Boehringer Ingelheim.
What was it about?
The project focused on extending the capabilities of the nf-core differential abundance pipeline by integrating limma/voom analysis with mixed models. This innovative approach improves RNA-seq analysis, particularly for handling incomplete paired-patient datasets—a common challenge in clinical studies. The enhanced pipeline promises more accurate gene expression profiling, helping researchers navigate complex clinical data more effectively.
If you’re curious to learn more, watch Kamil’s full talk:
